Side-by-side comparison of AI visibility scores, market position, and capabilities
San Jose clear aligner orthodontics inventor (NASDAQ: ALGN) at $3.23B 2024 revenue; 20 million Invisalign patient milestone Q1 2025 across 280,000+ doctors with iTero Lumina scanner competing with 3M Clarity for orthodontic clear aligner prescriptions.
Align Technology, Inc. is a San Jose, California-based global medical device company — publicly traded on NASDAQ (NASDAQ: ALGN) as an S&P 500 component — operating as the inventor of the Invisalign System and the world leader in clear aligner orthodontics, reaching 20 million Invisalign patients treated worldwide in Q1 2025 through a network of 280,000+ Invisalign-trained doctors across 100+ countries. In fiscal year 2024, Align reported $3.23 billion in total revenue with Q4 2024 revenue of $995.2 million (+4.0% year-over-year). Align's product portfolio comprises the Invisalign System of clear aligners, iTero intraoral digital scanners (including the iTero Lumina with 3X wider field of capture in a 50% smaller wand), and exocad CAD/CAM software for digital dental workflows. Manufacturing is based in Mexico with treatment planning performed in Costa Rica. CEO Joseph Hogan joined from GE Healthcare in 2015. Founded 1997 by Zia Chishti and Kelsey Wirth in San Jose.
Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.